Mortality Associated with Statins in Men with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy - Beyond the Abstract
A retrospective cohort study was conducted using the Taiwan Cancer Registry of 2008~2014. This study included 5749 men with locally advanced and metastatic PC who received only androgen deprivation therapy (ADT) in the first year after their cancer diagnosis. In this population study with 3.6 years of follow-up on average, patients showed a substantial decrease in mortality associated with statin use in men with metastatic disease following ADT. This is one of the largest patient populations with advanced PC following ADT, and results indicated the potential of statins as a therapy for men with non-metastatic high-risk and hormone-sensitive metastatic PC. Results also showed marked differences among individual statins, which provides important evidence for selecting the most appropriate statin for secondary prevention trials. Patients who received atorvastatin, pravastatin, rosuvastatin, or pitavastatin showed a stronger reduction in mortality than those who received other statins. This study focused on men with advanced prostate cancer patients with solely ADT treatment because that this is the group of patients who will gain the most benefit from adjuvant treatment if statins do decrease their all cause and prostate cancer mortality. While the 10-year survival among men with early stage prostate cancer is more than 90%, the benefit gained from statin in men with early stage prostate cancer is very small. This piece of evidence provides important information on the most appropriate target patient population and the types of statins for clinical trials to confirm the effects of statins in improving outcomes among men with prostate cancer.
Written by: Szu-Yuan Wu, MD, Assistant Professor, Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, Su-Chen Fang, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwa, Hung-Jen Shih, MD, PhD,Assistant Professor, Center for Cell Therapy and Regeneration Medicine, Taipei Municipal Wanfang Hospital, Department of Urology, Yu-Chin Wen, MS, PhD, Assistant Professor, Department of Urology, Taipei Municipal Wanfang Hospital, TMU Research Center of Cancer Translational Medicine, and Joni Yu-Hsuan Shao, MHS, PhD, Associate Professor, Graduate Institute of Biomedical Informatics, Taipei Medical University
Read the Abstract